{"nctId":"NCT00541450","briefTitle":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","startDateStruct":{"date":"2008-01-15","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":492,"armGroups":[{"label":"Sita/Met FDC","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: sitagliptin phosphate (sitagliptin)","Drug: sitagliptin phosphate (+) metformin hydrochloride","Drug: Matching placebo to pioglitazone"]},{"label":"Pioglitazone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: pioglitazone","Drug: Matching placebo to sitagliptin","Drug: Matching Placebo to Sita/Met FDC"]}],"interventions":[{"name":"Comparator: sitagliptin phosphate (sitagliptin)","otherNames":["MK0431, Januvia™"]},{"name":"sitagliptin phosphate (+) metformin hydrochloride","otherNames":["MK-0431A, Janumet™"]},{"name":"Comparator: pioglitazone","otherNames":["Actos®"]},{"name":"Matching placebo to pioglitazone","otherNames":[]},{"name":"Matching placebo to sitagliptin","otherNames":[]},{"name":"Matching Placebo to Sita/Met FDC","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients between the ages of 18 and 78 with type 2 diabetes mellitus\n* Patient has not been on any antihyperglycemic agent (Insulin or oral) in the last 3 months\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis\n* Patient has previously been treated with sitagliptin or has previously been in a study using a DPP-4 inhibitor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks","description":"The change in A1C, compared to baseline for the Sita/Met FDC and the pioglitazone groups at Week 40. A1C represents percentage of glycosylated hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":null},{"groupId":"OG001","value":"-1.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose (PMG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks","description":"The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the Sita/Met FDC and the pioglitazone groups at Week 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.3","spread":null},{"groupId":"OG001","value":"-69.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Hemoglobin A1c (A1C) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks","description":"The change in A1C compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. A1c represents percentage of glycosylated hemoglobin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":null},{"groupId":"OG001","value":"-0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose (PMG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks","description":"The change in PMG compared to baseline was measured using the Meal Tolerance Test (MTT) for the participants treated with Sitagliptin or Pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.8","spread":null},{"groupId":"OG001","value":"-50.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) in the Sita/Met FDC or Pioglitazone Groups at 40 Weeks","description":"The change in FPG compared to baseline was measured for the Sita/Met FDC and the pioglitazone groups at Week 40.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.8","spread":null},{"groupId":"OG001","value":"-37.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) in Participants Treated With Sitagliptin or Pioglitazone at 12 Weeks","description":"The change in FPG compared to baseline was measured for the participants treated with sitagliptin or pioglitazone at Week 12. Sitagliptin was the only intervention administered to the Sita/Met FDC group during this phase. To calculate Least Squares, the ANCOVA model included a term for treatment and the baseline value as a covariate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.6","spread":null},{"groupId":"OG001","value":"-28.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":244},"commonTop":["Nasopharyngitis","Headache","Oedema peripheral"]}}}